{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:48:04Z","timestamp":1788220084541,"version":"build-2803163510"},"reference-count":15,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Recently, a randomized controlled trial suggested a potential benefit of baricitinib in patients with diabetes mellitus, preserving \u03b2-cell function. However, the clinical evidence currently available is limited. We aimed to assess the potential impact of tofacitinib and baricitinib on type 2 diabetes mellitus (T2DM) patients with rheumatoid arthritis. Materials and Methods: The candidates for this observational, retrospective, single-center study were selected from a cohort of 120 rheumatoid arthritis patients treated with tofacitinib or baricitinib between September 2017 and September 2023. The eligibility criteria included patients with T2DM who were receiving oral antidiabetic drugs (OADs). The primary outcome was the glycosylated hemoglobin (HbA1c) value after 6 months of a JAK inhibitor treatment. Secondary outcomes included body mass index (BMI) and rheumatoid arthritis disease activity. Differences were evaluated using Fisher\u2019s exact test, as well as the Mann\u2013Whitney test or the Wilcoxon test. Results: Thirteen patients were included; 46.2% (6\/13) underwent treatment with tofacitinib, while 53.8% (7\/13) were treated with baricitinib. At 6 months, baricitinib treatment resulted in a reduction in HbA1c (p = 0.035), with 57.1% (4\/7) of patients achieving values &lt;7%, and 28.6% (2\/7) of patients requiring a reduction in OAD dosage. Concerning BMI, an increase (p = 0.022) was observed at 6 months following baricitinib administration. All the patients treated with either tofacitinib or baricitinib achieved remission or low disease activity, without requiring statistically significant changes in concomitant rheumatoid arthritis treatment. Conclusions: In T2DM patients with rheumatoid arthritis, baricitinib can improve insulin sensitivity and glucose uptake, enabling the optimization of T2DM management.<\/jats:p>","DOI":"10.3390\/medicina60030360","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T10:52:00Z","timestamp":1708512720000},"page":"360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5079-613X","authenticated-orcid":false,"given":"Cristina","family":"Martinez-Molina","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6275-7699","authenticated-orcid":false,"given":"Cesar","family":"Diaz-Torne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Department of Rheumatology and Systemic Autoimmune Diseases, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-9527","authenticated-orcid":false,"given":"Hye S.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Department of Rheumatology and Systemic Autoimmune Diseases, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-2231","authenticated-orcid":false,"given":"Anna","family":"Feliu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-6682","authenticated-orcid":false,"given":"Silvia","family":"Vidal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Group of Immunology-Inflammatory Diseases, Sant Pau Biomedical Research Institute (IIB Sant Pau), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-6787","authenticated-orcid":false,"given":"H\u00e8ctor","family":"Corominas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Department of Rheumatology and Systemic Autoimmune Diseases, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tem.2017.11.001","article-title":"JAK\/STAT\u2014Emerging Players in Metabolism","volume":"29","author":"Dodington","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2337\/diabetes.55.04.06.db05-1265","article-title":"Opposite effect of JAK2 on insulin-dependent activation of mitogen-activated protein kinases and Akt in muscle cells: Possible target to ameliorate insulin resistance","volume":"55","author":"Thirone","year":"2006","journal-title":"Diabetes"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1245535","DOI":"10.3389\/fphar.2023.1245535","article-title":"Recent advances in JAK inhibitors for the treatment of metabolic syndrome","volume":"14","author":"Collotta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and \u03b2-Cell Function in Patients with New-Onset Type 1 Diabetes","volume":"389","author":"Waibel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1111\/febs.13709","article-title":"The JAK\/STAT pathway in obesity and diabetes","volume":"283","author":"Gurzov","year":"2016","journal-title":"FEBS J."},{"key":"ref_8","unstructured":"European Medicines Agency\u2014EMA (2023, December 20). Tofacitinib: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf."},{"key":"ref_9","unstructured":"European Medicines Agency\u2014EMA (2023, December 20). Baricitinib: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/annrheumdis-2021-221840","article-title":"Hypoglycaemia following JAK inhibitor treatment in patients with diabetes","volume":"81","author":"Tas","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101009","DOI":"10.1016\/j.molmet.2020.101009","article-title":"Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice","volume":"39","author":"Collotta","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117045","DOI":"10.1016\/j.lfs.2019.117045","article-title":"Inhibition of JAK-STAT and NF-\u03baB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes","volume":"239","author":"Bako","year":"2019","journal-title":"Life Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/nature01388","article-title":"STAT3 signalling is required for leptin regulation of energy balance but not reproduction","volume":"421","author":"Bates","year":"2003","journal-title":"Nature"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:33Z","timestamp":1760104953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["medicina60030360"],"URL":"https:\/\/doi.org\/10.3390\/medicina60030360","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}